| (Values in U.S. Thousands) | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 |
| Sales | 103,140 | 76,260 | 36,660 | 5,620 | 0 |
| Sales Growth | +35.25% | +108.02% | +552.31% | unch | unch |
| Net Income | 11,920 | -16,320 | -33,830 | -42,960 | -70,840 |
| Net Income Growth | +173.04% | +51.76% | +21.25% | +39.36% | -174.68% |
Verona Pharma Plc ADR
(VRNA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom.
Fiscal Year End Date: 12/31